Literature DB >> 19267844

Phosphodiesterase type 5 regulation in the penile corpora cavernosa.

Ching-Shwun Lin1.   

Abstract

INTRODUCTION: Penile detumescence depends on the hydrolysis of cyclic guanosine monophosphate (cGMP) by phosphodiesterase type 5 (PDE5). It is hoped that a review of publications relevant to the regulation of PDE5 in the penis will be helpful to both scientists and clinicians who are interested in the sciences of erectile function/dysfunction. AIMS: The aim of this article is to comprehensively review the mechanisms by which PDE5 activity and expression in the penis are regulated. All published studies relevant to PDE5 regulation in the penis or penile cells will be reviewed.
METHODS: Entrez (PubMed) was used to search for publications relevant to the topics of this review. Keywords used in the searches included vascular, cavernous, penis, smooth muscle, signaling molecules, erection, priapism, and PDE5. Articles that are dedicated to the study of erectile function/dysfunction were prioritized for citation.
RESULTS: Regulation of PDE5 can occur at both protein and gene levels. At protein level, PDE5 is activated by phosphorylation and/or allosteric cGMP binding. Deactivation is carried out by protein phosphatase 1 and thus linked to the Rho-kinase signaling pathway. Cleavage of PDE5 into an inactive form has been shown as carried out by caspase-3. At the gene level, PDE5 expression is regulated at two alternative promoters, PDE5A and PDE5A2, both of which are positively regulated by cyclic adenosine monophosphate and cGMP. Downregulation of PDE5 has been observed in the penis of castrated animals; however, proof of androgen regulation of PDE5 gene requires examination of the smooth muscle content. Hyperoxia and hypoxia, respectively, regulate PDE5 expression positively and negatively. Hypoxic downregulation of PDE5 is a possible mechanism for the development of priapism.
CONCLUSIONS: PDE5 can be regulated at protein and gene levels. In the penis, changes of PDE5 activity have been linked to its phosphorylation status, and downregulation of PDE5 expression has been associated with hypoxia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267844     DOI: 10.1111/j.1743-6109.2008.01179.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  8 in total

1.  Nitric oxide-induced vasorelaxation in response to PnTx2-6 toxin from Phoneutria nigriventer spider in rat cavernosal tissue.

Authors:  Kenia P Nunes; Marta N Cordeiro; Michael Richardson; Marcia N Borges; Simone O F Diniz; Valbert N Cardoso; Rita Tostes; Maria Elena De Lima; Robert Clinton Webb; Romulo Leite
Journal:  J Sex Med       Date:  2010-08-16       Impact factor: 3.802

2.  Long-term testosterone supplementation is useful for ED with testosterone deficiency.

Authors:  Tao Jiang; Lei Zheng; Xiao-Ming Su; Jin-Qiang Peng; Dong-Chen Sun; Quan-Lin Li; Zhi-Wei Zhang; Fa-Peng Wang; Hui Jiang
Journal:  Asian J Androl       Date:  2013-06-24       Impact factor: 3.285

Review 3.  Role of adenosine signaling in penile erection and erectile disorders.

Authors:  Prasad V Phatarpekar; Jiaming Wen; Yang Xia
Journal:  J Sex Med       Date:  2010-11       Impact factor: 3.802

4.  Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP.

Authors:  Yuji Ishibashi; Takanori Matsui; Masayoshi Takeuchi; Sho-ichi Yamagishi
Journal:  Clin Exp Med       Date:  2010-08-29       Impact factor: 3.984

Review 5.  A pathophysiology-based approach to the management of early priapism.

Authors:  Jason R Kovac; Siu K Mak; Maurice M Garcia; Tom F Lue
Journal:  Asian J Androl       Date:  2012-12-03       Impact factor: 3.285

6.  Dipyridamole reduces penile apoptosis in a rat model of post-prostatectomy erectile dysfunction.

Authors:  Omer Kutlu; Ersagun Karaguzel; Ali Ertan Okatan; Ahmet Mentese; Esin Yulug; Ilke Onur Kazaz; Selcuk Kutlu; Eyup Dil; Huseyin Eren; Ahmet Alver
Journal:  Int Braz J Urol       Date:  2017 Sep-Oct       Impact factor: 1.541

Review 7.  Defining the Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors with Tamsulosin for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia with or without Erectile Dysfunction: A Network Meta-Analysis.

Authors:  Chengquan Ma; Jianzhong Zhang; Zhonglin Cai; Jian Xiong; Hongjun Li
Journal:  Biomed Res Int       Date:  2020-03-26       Impact factor: 3.411

8.  Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats.

Authors:  Tomoya Kataoka; Yuto Kawaki; Yohei Kito; Jun Suzuki; Taiki Mori; Yuji Hotta; Akimasa Sanagawa; Yoshihiro Kawade; Yasuhiro Maeda; Yoko Furukawa-Hibi; Kazunori Kimura
Journal:  Sex Med       Date:  2022-01-19       Impact factor: 2.523

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.